Retatrutide Research

Retatrutide Structure and Sequence

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-233 cited sources

The short answer

Retatrutide is a 39-residue synthetic peptide built on a modified GIP scaffold, with a C20 fatty diacid conjugated through a γGlu-2xOEG linker at Lys17. The lipid binds serum albumin, extending half-life; the substitutions across the backbone create balanced activity at three receptors.

Key facts

Residues
39
Backbone
Modified GIP scaffold
Lipidation site
Lys17
Linker
γGlu-2xOEG
Fatty acid
C20 diacid
Receptors
GIPR, GLP-1R, GCGR
Primary reference
Coskun, Cell Metab 2022

Why the backbone is GIP

This is the design decision that defines the molecule, and it is the same one Lilly made with tirzepatide. Rather than starting from GLP-1 and adding activity, both compounds start from GIP and engineer in the others. The three receptors (GIP, GLP-1 and glucagon) belong to one structurally related family, which is what makes a single scaffold capable of engaging all of them plausible at all.

What balanced agonism means

Balanced does not mean equal. It means the potencies at the three receptors sit within a range where all three contribute meaningfully at achievable concentrations, rather than one dominating so completely that the others are irrelevant. Achieving that across three related but distinct receptors, from one sequence, is the hard part of the design.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The lipid and what it does

A C20 fatty diacid attached at Lys17 through a γGlu-2xOEG spacer. The diacid binds reversibly to serum albumin, which is too large to be filtered by the kidney and shields the peptide from proteases. This is the same strategy semaglutide uses with a C18 diacid and liraglutide with C16 palmitic acid, with chain length tuning the strength of binding and therefore the half-life.

Why the linker is not padding

The γGlu-2xOEG spacer sets the distance and flexibility between the albumin-binding lipid and the receptor-binding peptide. Get it wrong and albumin binding sterically blocks the peptide from reaching its receptors, or the lipid cannot reach albumin. It is a real design parameter rather than a connector.

Why Lys17 specifically

Lipidation needs a lysine side-chain amine to attach to, and it needs to be at a position where a bulky substituent does not interfere with receptor contact. Position 17 satisfies both. The same logic places semaglutide's chain at Lys26 and tirzepatide's at Lys20, each chosen for the same reasons within a different sequence.

Where the sequence is published

Coskun and colleagues described the discovery and characterisation of LY3437943 in Cell Metabolism in September 2022, and the sequence has appeared in Eli Lilly patent filings. That paper is the primary structural reference for anything in this article.

Frequently asked questions

How long is retatrutide?

39 residues, plus a C20 fatty diacid conjugated at Lys17 through a γGlu-2xOEG linker.

Why build it on GIP rather than GLP-1?

The three target receptors belong to one related family, and the GIP scaffold proved the workable starting point. It is the same choice Lilly made for tirzepatide.

What does the fatty acid do?

It binds serum albumin reversibly, which prevents renal filtration and shields the peptide from proteases, extending half-life.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More Retatrutide Research articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.